The introduction of an organised cervical screening programme in the United Kingdom in 1988 has led directly to a fall in the annual number of new cases of invasive cervical cancer. The NHS cervical screening programme has been estimated to prevent up to 3900 cases of cervical cancer ([@bib16]; [@bib12]) and save approximately 4500 lives per year by 2030 ([@bib13]).

Infection with high-risk human papillomavirus (HPV) is now known to be a necessary aetiological factor in the development of cervical cancer ([@bib11]). Those strains of HPV associated with genital tract infection are subdivided into high- and low-risk types, and of the former HPV 16 and 18 are estimated to be responsible for over 70% of all cases of cervical cancer ([@bib7]). Testing liquid residue from samples with borderline cytological abnormalities or mild dyskaryosis for high-risk HPV DNA can identify those women who are at risk of disease from those who have only a negligible risk of high-grade CIN. A meta-analysis has found that the use of HPV testing for triage in this way improved the accuracy for ASCUS samples for an outcome of CIN2 or worse compared with repeat cytology ([@bib1]).

In 2001, the HPV/liquid-based cytology (LBC) pilot studies reported on the feasibility of introducing HPV triage in the English screening programme. Three sites converted to using LBC and HPV triage with the Hybrid Capture 2 (HC2) assay for women with borderline cytology or mild dyskaryosis. Initially all HPV-positive women were referred to colposcopy, whereas HPV-negative women were re-tested at 6 months and referred to colposcopy if found to be HPV-positive or cytology of mild dyskaryosis or worse. Readings greater than three times the kit derived cutoff (Co) value in relative light units (RLUs) were considered positive (\>3 RLU/Co). The protocol was amended in two sites, where HPV-positive women aged under 35 years were re-tested at 6 months and only referred to colposcopy if HPV infection and/or cytological abnormality persisted. The results of the pilot study suggested that although HPV triage decreased the number of repeat cytology tests and reduced the time taken to return women to routine recall, it resulted in a large increase in referrals to colposcopy. Nevertheless, not only was HPV triage feasible and acceptable to women but also the results of an economic analysis concluded that it was cost-effective, both in terms of quality and of life years saved ([@bib9]; [@bib10]).

In 2007, the 'Sentinel sites\' protocol was implemented, representing ∼10% of the English cervical screening programme. The sites included two from the original pilots (Bristol and Norfolk and Norwich), and four additional ones (Liverpool, Manchester, Sheffield and Northwick Park). An agreed protocol for the use of HPV triage for women with borderline or mild dyskaryosis was followed.

The evaluation of this project aimed to provide information on the likely effect of national rollout, including rates of referral to colposcopy, and the positive predictive value (PPV) of this approach.

Materials and methods
=====================

Samples from women, aged 25--64 years, undergoing routine call or recall cytology at the six sites reported as borderline or mild dyskaryosis, were included in the protocol.

Cytology was liquid based; three sites used ThinPrep LBC (Hologic, Bedford, MA, USA), two sites used BD SurePath LBC (Beckton Dickinson, Franklin Lakes, NJ, USA) and one site used both the technologies. Samples reported as borderline or mild dyskaryosis were sent to one of two HPV testing laboratories serving all six of the sentinel sites. The Qiagen HC2 (Crawley, England) assay was used, with a cut-off of 2 RLU/Co to determine positivity ([@bib15]).

The protocol is shown in [Figure 1](#fig1){ref-type="fig"}. Women who tested negative for HPV were returned to routine recall at 3 or 5 years, depending on age; those who were HPV-positive were referred to colposcopy. Women who appeared normal at colposcopic inspection and those found to have no CIN on biopsy were returned to routine recall. Women diagnosed with CIN1 on biopsy and who were not treated underwent a 12-month surveillance cytology. Women with CIN2 or worse were treated and followed up with a test of cure protocol. This comprised of repeat cytology at 6 months and a reflex HPV test in those with negative cytology, with referral to colposcopy if either was positive; all other women were returned to routine recall at 3 years (regardless of age). The results of the analysis of the test of cure protocol will be presented elsewhere, as will be data on cost-effectiveness. Anonymous data on relevant cytology HPV tests, RLU values, biopsy, treatment and histology were collected, together with information on management and reasons for non-attendance.

The study took place between 1 January 2008 and 1 April 2009. Follow-up data were collected until September 2009, with additional data requested for those individual women with outstanding cytology and/or colposcopy outcomes. Statistical analysis was conducted using STATA version 10 (Stata Corporation, College Station, TX, USA). Age standardisation used 5-year age groups, standardised to the European standard population ([@bib21]).

The epidemiological evaluation was carried out by the Cancer Screening Evaluation Unit.

Results
=======

A total of 10 051 women entered the protocol; 6507 (64.7%) had an initial borderline test and 3544 (35.3%) had initial mild dyskaryosis.

HPV-positive rates
------------------

Of these 10 051 women, 6470 (64.4%) tested positive for high-risk HPV, 53.7% of those with a borderline test and 83.9% of those with mild dyskaryosis. There was a highly significant decreasing trend in HPV-positive rate with increasing age (*P*\<0.0001) in both categories. Less than 2% of HPV-positive women had an RLU value of between 2 and 3. The profiles of the study participants are shown in [Table 1](#tbl1){ref-type="table"}.

The HPV-positive rates at the six sites ranged from 34.8% to 73.3% for women with borderline cytology, and from 73.4% to 91.6% for women with mild dyskaryosis. ([Table 2](#tbl2){ref-type="table"}) These differences remained after the rates were standardised for age. Overall the HPV-positive rate was higher in sites using ThinPrep LBC than in those using BD SurePath LBC; 68.7% and 61.7%, respectively, (*P*\<0.0001). The difference remained after adjustment for age group and initial cytology result. LBC technology was, however, confounded by site, and it was therefore not possible to determine whether this difference was due to variation in the reporting of cytology between sites. In the only site which used both technologies there was no significant difference in positive rates between the two.

Colposcopy following a positive HPV test
----------------------------------------

At least 6 months follow-up was available for all 6470 HPV-positive women, of which 5838 (90.2%) attended colposcopy. Attendance varied from 96.2% to 81.4% between sites. No information was available on the remaining 632 who failed to attend.

[Table 3](#tbl3){ref-type="table"} shows the outcome at colposcopy in the 5838 women who attended. The proportion of women who were negative at colposcopy, due either to a negative biopsy or to a negative colposcopic assessment, resulting in no biopsy being performed, was significantly higher in women with initial borderline cytology than in women with mild dyskaryosis, 59.9% and 48.3%, respectively, (*P*\<0.0001). Overall, 29% of these had no biopsy.

There were 298 colposcopies for which information on biopsy type was not available or was coded as 'other\'. Nearly 19% (1093 out of 5838) of women who attended colposcopy were reported as not undergoing biopsy, although 16.0% (175 out of 1093) of these women had a recorded diagnosis of CIN1. Almost 63% (3631 out of 5838) of all women who attended colposcopy underwent a diagnostic punch biopsy, of which 49.0% (1778 out of 5838) were negative for CIN. Excision biopsy by LLETZ was reported in 196 women, of whom only 114 (58.2%) were found to have CIN2 or worse, and almost 30% (56) were negative for CIN. A further 442 women were known to have had a biopsy, but the type was not specified.

The type of procedure performed at colposcopy varied greatly by centre, with the percentage of women not undergoing biopsy varying from 65.9% to 2.7%, and the proportion undergoing punch biopsy varying from 26.5% to 95%.

Positive predictive value
-------------------------

The PPV of a positive HPV test for detecting high-grade CIN in women who attended colposcopy was 6.1% for CIN3 or worse and 16.3% for CIN2 or worse ([Table 3](#tbl3){ref-type="table"}). The PPV for CIN3 or worse was slightly, but significantly, higher in women with initial borderline cytology than in women with initial mild dyskaryosis (6.7% *vs* 5.4% *P*=0.03); but this was not observed for CIN2 or worse. There was a highly significant decreasing trend in the PPV for CIN2 or worse with increasing age group (*P*\<0.0001), which was observed both in women with initial borderline and initial mild dyskaryosis.

The PPV of HPV for detecting high-grade disease varied by centre ([Table 4](#tbl4){ref-type="table"}); the PPV for CIN2 or worse ranged from 9.3% to 21.5% and for CIN3 or worse from 2.5% to 11.5% for women with borderline changes at cytology. For women with mild dyskaryosis, the PPV for CIN2 or worse ranged from 9.1% to 33.0% and for CIN3 or worse from 2.5% to 15.2%. Standardising for age and for the ratio of borderline to mild tests did not reduce this variation.

Discussion
==========

This study is indicative of the impact of rolling out of HPV triage, in terms of colposcopy referral and detection of CIN2+. The principal findings are that referral rates following triage varied across clinical sites, and the proportion of referred women with CIN2+ (PPV) varied. The strength of this study was its real-life response to HPV triage as routine NHS practice across six sites in England. The main limitation of this study was that its observational nature resulted in a number of women not being managed according to protocol, and follow-up was, therefore, incomplete at the time of end of data collection. We believe, however, that the results for the large majority of women who did attend following referral are representative of the cohort as a whole.

The HPV-positive proportion in the current study was higher than that observed in the pilot studies of 2003--2004. As a result, referral to colposcopy of 64% was significantly higher than that observed with both the initial (48%) and the revised (38%) protocol of the pilot studies, despite women who were HPV-negative being returned immediately to routine recall. The PPVs of HPV for CIN2 or worse and CIN3 or worse were lower in the present study than those observed in the earlier pilot studies; 6.1% *vs* 8.3% for CIN3+ (*P*=0.004) and 16.3% *vs* 20.0% for CIN2+ (*P*=0.0014). The attendance rate for colposcopy was high (90.2%), and greater than that of 72% seen in a similar UK-based study for women with a borderline cytology result, a positive HPV test or both ([@bib5]). The higher HPV-positive rates observed in this study are not readily explained by the lower cut-off for a positive test of 2 RLU/Co compared with 3 RLU/Co in the earlier studies, as the proportion of women with RLU/Co between 2.0 and 3.0 was small. They may be due, in part, to changes in the demographics of the populations, and changes in sampling technique or perhaps more likely, due to cytological classification. The HPV-positive rates observed in this study, overall, are also higher than those observed in other studies. In the UK-based ARTISTIC trial, which had a high rate of borderline cytology, the HPV-positive rate was 31.1% for borderline cytology and 69.9% for mild dyskaryosis ([@bib8]). A meta-analysis ([@bib2]) found an average HPV-positive rate of 43% (95% CI: 40--46%) for women with ASCUS/ASC-US (broadly comparable to borderline cytology) and 76% (95% CI: 71--81%) for women with LSIL (broadly comparable to mild dyskaryosis).

Of importance was the observed difference between sites in HPV-positive rates. The threshold used to determine borderline and mild dyskaryosis test results will vary between laboratories. According to a 3-year average from the NHSCSP screening returns (KC61 part B: 2006--07, 2007--08 and 2008--09), the two sites with the lowest rate of HPV-positive tests classified a higher percentage of all samples taken as borderline or worse than do the other sites, suggesting that they may be including samples in their borderline changes category that other laboratories would class as negative.

Heterogeneity in HPV-positive rates between studies has also been observed in a meta-analysis of studies of triage in women with ASCUS/LSIL cytology ([@bib2]). The rates in the current study are within the observed range of this meta-analysis.

Both HPV testing laboratories participated in external quality control provided by the National External Quality Assessment Service and by the Scottish HPV reference laboratory, in addition to internal quality assurance (QA) procedures with retesting of 2% of all samples. There was variation in the PPV between the sites tested by each HPV testing laboratory.

The lower PPV values observed in this study may be a consequence of higher HPV-positive rates, if these are not related to a higher prevalence of CIN. The differences between sites may reflect the different rates of cytological abnormality and HPV positivity in the sites participating. Because this was a pragmatic study, there was no additional QA of the colposcopy, but all colposcopists taking part are BSCCP certified and take part in the NHSCSP QA programme. There was considerable variation in rates of punch biopsy, which implies variation in local practice and in part explains the variation in rates of high-grade CIN. In 29% (997 out of 3187) of the colposcopy results reported as negative, no biopsy was taken, but there is no evidence that the variation in PPV between sites is related to the variation in biopsy rate.

The variation in the PPV of a positive HPV test is also reflected in the literature; estimates range from a PPV of 8.3% ([@bib6]) to 58.1% ([@bib14]) for ASCUS and CIN2+ and 8.4% ([@bib4]) to 54.5% ([@bib14]) for LSIL and CIN2+. A meta-analysis has found a pooled PPV of 22.3% for ASCUS and 27.3% for LSIL ([@bib3]). The PPV of an HPV test for high-grade disease appears more dependent on age than on the grade of cytology, which may be indicative that high-risk HPV is more important than whether a sample is classified as borderline or mild.

The results of the original pilot studies suggested that referring all HPV-positive women to colposcopy led to an earlier detection of CIN2+ compared with standard practice, however this effect was not observed for CIN3+. The revised protocol for women aged 25--34 years adopted for part of these studies reduced the colposcopy workload somewhat, but 75% of women remained HPV-positive at 6 months, and such a policy increased the number of repeat smears and the risk of loss to follow-up. The UK-based TOMBOLA trial ([@bib18], [@bib19], [@bib20]) recommended a policy of surveillance rather than triage for two reasons; the first was that some CIN2+ will regress with time and the second was that they identified a high proportion of HPV-negative CIN 2. HPV-negative CIN2 is, however, probably of little clinical significance. The high rate of compliance with colposcopy indicates that triage is acceptable to women, and the ability to return to recall not only 50% of those referred to colposcopy but also the 35% of women who were HPV-negative are both significant benefits ([@bib18], [@bib19], [@bib20]).

Although the HPV-positive rate in women with mild dyskaryosis is high, the negative predictive value of an HPV test in these women is over 96% ([@bib10]), and the use of triage allows 16% of these women to be returned to routine recall.

The difference in HPV-positive rates between the centres involved in this project highlights the inter-laboratory variation in grade classification, which will be reflected in any wider rollout of HPV triage around the country, in terms of rates of referral to colposcopy. It also highlights the need for efficient management of HPV-positive women found to be negative at colposcopy. The PPV for CIN2 or worse, 16%, was relatively low, which suggests that although HPV triage is a useful tool for returning women at low risk to routine recall, further refinement of triage should be considered to improve PPV without loss of sensitivity. This could exploit HPV genotyping and biomarkers, both of which have been shown to be capable of improving specificity ([@bib17]), with the need to avoid increasing reporting times.
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###### HPV-positive rates by age group and initial cytology result

           **Borderline**   **Mild**      **Total**                          
  -------- ---------------- ------------- ----------- ------------- -------- -------------
  25--34   3121             2144 (68.7)   2203        1964 (89.2)   5324     4108 (77.2)
  35--49   2783             1165 (41.9)   1129        869 (77.0)    3912     2034 (52.0)
  50--64   603              187 (31.0)    212         141 (66.5)    815      328 (40.2)
  Total    6507             3496 (53.7)   3544        2974 (83.9)   10 051   6470 (64.4)

Abbreviation: HPV=human papillomavirus.

###### HPV-positive rates by site and initial cytology

                            **Borderline**   **Mild**      **Total**                        
  ------------------------- ---------------- ------------- ----------- ------------- ------ -------------
  A                         789              455 (57.7)    420         372 (88.6)    1209   827 (68.4)
  B                         643              224 (34.8)    523         384 (73.4)    1166   608 (52.1)
  C                         2557             1111 (43.4)   1507        1232 (81.8)   4064   2343 (57.7)
  D                         663              406 (61.2)    557         500 (89.8)    1220   906 (74.3)
  E                         1263             866 (68.6)    404         370 (91.6)    1667   1236 (74.1)
  F                         592              434 (73.3)    133         116 (87.2)    725    550 (75.9)
  C (Thinprep LBC)          1188             543 (47.7)    798         669 (83.8)    1986   1212 (61.0)
  C (BD Surepath LBC)       426              216 (50.7)    241         204 (84.6)    667    420 (63.0)
  Total (Thinprep LBC)      3903             2270 (58.2)   2179        1911 (87.7)   6082   4181 (68.7)
  Total (BD Surepath LBC)   1661             874 (52.6)    897         704 (78.5)    2558   1578 (61.7)

Abbreviations: HPV=human papillomavirus; LBC=liquid-based technology.

Technology not known for 943 borderline and 468 mild samples.

###### Results of follow-up of HPV-positive women

             **Inadequate/unknown/other, *n* (%)**   **Negative, *n* (%)**   **Positive cytology, *n* (%)**   **CIN1, *n* (%)**   **CIN2, *n* (%)**            **CIN3+, *n* (%)**            **Total, *n* (%)**
  --------- --------------------------------------- ----------------------- -------------------------------- ------------------- ------------------- -------------------------------------- --------------------
  *BL*                                                                                                                                                                                      
   25--34                  64 (3.3)                       1091 (56.6)                   45 (2.3)                 394 (20.4)          193 (10.0)       142[a](#t3-fn2){ref-type="fn"} (7.4)      1929 (100.0)
   35--49                  30 (2.8)                       679 (64.0)                    26 (2.5)                 173 (16.3)           88 (8.3)                      65 (6.1)                    1061 (100.0)
   50--64                   8 (4.7)                       124 (72.5)                    3 (1.8)                   27 (15.8)            4 (2.3)                      5 (2.9)                     171 (100.0)
   Total                   102 (3.2)                      1894 (59.9)                   74 (2.3)                 594 (18.8)           285 (9.0)                    212 (6.7)                    3161 (100.0)
                                                                                                                                                                                                      
  *Mild*                                                                                                                                                                                    
   25--34                  71 (4.1)                       821 (46.9)                    62 (3.5)                 468 (26.7)          217 (12.4)                    111 (6.3)                    1750 (100.0)
   35--49                  27 (3.4)                       392 (49.2)                    25 (3.1)                 236 (29.6)           87 (10.9)                     30 (3.8)                    797 (100.0)
   50--64                   3 (2.3)                        80 (61.5)                    5 (3.8)                   31 (23.8)            8 (6.2)                      3 (2.3)                     130 (100.0)
   Total                   101 (3.8)                      1293 (48.3)                   92 (3.4)                 735 (27.5)          312 (11.7)                    144 (5.4)                    2677 (100.0)
                                                                                                                                                                                                      
  Total                    203 (3.5)                      3187 (54.6)                  166 (2.8)                 1329 (22.8)         597 (10.2)                    356 (6.1)                    5838 (100.0)

Abbreviations: BL=borderline; CIN=cervical intraepithelial neoplasia; HPV=human papillomavirus.

Includes three invasive cancers.

###### PPV of colposcopy by site

      **Borderline**   **Mild**   **Total**                                      
  --- ---------------- ---------- ----------- ------ ------ ------ ------ ------ ------
  A   430              16.5       7.4         354    21.8   7.6    784    18.9   7.5
  B   178              11.2       6.2         317    9.1    3.5    495    9.9    4.4
  C   978              11.6       5.0         1104   15.9   4.8    2082   13.9   4.9
  D   355              9.3        2.5         440    10.9   2.5    795    10.2   2.5
  E   803              21.5       7.8         350    25.4   7.1    1153   22.7   7.6
  F   417              20.9       11.5        112    30.0   15.2   529    23.4   12.3

Abbreviations: CIN=cervical intraepithelial neoplasia; PPV=positive predictive value.

[^1]: See [Appendix](#app1){ref-type="app"}.
